Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57results about How to "Constant plasma concentration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compound aescine A and B liposome hydrogel patch
ActiveCN107028919AExtended treatment timeWith slow and controlled release effectSalicyclic acid active ingredientsAntipyreticMedicineLiposome
The invention discloses a swelling-resistant pharmaceutical composition. The swelling-resistant pharmaceutical composition comprises aescine A or salt thereof, aescine B of salt thereof and diethylamine salicylate according to the proportion of (0.3-1.5):(0.5-1):(2-5). The invention further discloses a compound aescine A and B liposome hydrogel patch containing the swelling-resistant pharmaceutical composition and a preparation method of the compound aescine A and B liposome hydrogel patch. Compared with the prior art, the compound aescine A and B liposome hydrogel patch is good in transdermal absorption effect, swelling-resistant effect and safety.
Owner:WUHAN AIMIN PHARMA
Huperzine A mono-layer osmotic pump controlled release tablets
InactiveCN101485640AStable release rateConstant plasma concentrationOrganic active ingredientsNervous disorderWeight gainDrug release rate
The invention discloses a huperzine A single-layer osmotic pump controlled-release tablet. The controlled-release tablet comprises a tablet core containing huperzine A and pharmaceutic adjuvants in effective dosage, and a semipermeable coating membrane coating the tablet core, wherein the coating membrane is provided with a drug release hole. The controlled-release tablet is characterized in that: the tablet core contains the following components in percentage by weight: 0.01 to 1.0 percent of huperzine A, 1.0 to 10 percent of retarder and 1.0 to 40 percent of permeation enhancer; and the weight ratio of polyethylene glycol 6,000 contained in the coating liquid to cellulose acetate is (0.05-0.25):1, and the weight gain of the coating membrane against the weight of the tablet core is between 5 and 25 percent. The controlled-release tablet has the advantages that the drug release rate is stable, the blood consentration of patients is relatively constant after the patients take the controlled-release tablet, and the drug taking frequency of the patients is reduced, so that the controlled-release tablet is a novel drug formulation which is safer, more effective, stable, controllable and convenient for application in clinically treating senile dementia.
Owner:普尔药物科技开发(深圳)有限公司
Composition of beta-nicotinamide mononucleotide or beta-nicotinamide mononucleotide precursor, and preparation method and application of composition
InactiveCN111166760AImprove internal functionTo promote metabolismOrganic active ingredientsMetabolism disorderLiver and kidneyBlood concentration
The invention relates to the field of biological medicines, and in particular to a composition of beta-nicotinamide mononucleotide or a beta-nicotinamide mononucleotide precursor, and a preparation method and application of the composition. The composition comprises the following raw materials in percentage by weight: 0.001 to 25 percent of beta-nicotinamide mononucleotide or a precursor thereof,0 to 20 percent of a transdermal absorption enhancer, 2 to 50 percent of an auxiliary component and the balance of water. After being absorbed by a human body in a mode of transdermal administration or external administration, the composition can exert effects of improving internal functions of a human body, improving metabolism of a human body or improving epidermal functions of a human body, andresisting skin inflammation, allergy and skin aging. Through the mode of transdermal administration and external administration, metabolic burden of liver and kidney can be avoided, blood concentration can be kept constant, and administration is convenient.
Owner:浙江安赛新材料科技有限公司
Compound anti-aging quercetin nanoemulsion health care product
InactiveCN102631385ASignificant and long-lasting antioxidantVisible and long-lasting anti-aging effectOrganic active ingredientsAntinoxious agentsAcute hyperglycaemiaDisease
The invention discloses a compound anti-aging quercetin nanoemulsion health care product which comprises the following raw materials in mass percent: 1-15% of quercetin, 15-40% of surfactant, 1-15% of cosurfactant, 5-25% of oil, 1-15% of celery aqueous extract, 1-15% of mushroom aqueous extract, and the balance of distilled water; and the sum of mass percents of the above raw materials is 100%. The nanoemulsion is small in emulsion droplet, uniform in distribution, low in viscosity and good in liquidity. The compound anti-aging health care product takes fat soluble natural product quercetin with an efficient anti-aging effect as a main component, takes the celery aqueous extract and the mushroom aqueous extract as auxiliary components, has effects of keeping skin moisture, adjusting slumber, delaying senescence and adjusting immunologic function and has certain health care effect on diseases such as hypertension, hyperlipemia, hyperglycemia, heart disease and the like.
Owner:NORTHWEST A & F UNIV
Transdermal delivery preparation in three-dimensional netty spatial configuration of agomelatine and preparation method thereof
ActiveCN103830206AAvoid oral gastrointestinalAvoid liver first pass effectOrganic active ingredientsNervous disorderBlood concentrationSilicon dioxide
The invention discloses a transdermal delivery preparation in three-dimensional netty spatial configuration of agomelatine and a preparation method thereof. The transdermal delivery preparation consists of a backing layer, a medicine-loading system in a three-dimensional netty spatial configuration coated on the backing layer and an anti-sticking layer compounded on the system. The medicine-loading system in the three-dimensional netty spatial configuration comprises the following components in percentage by weight: 1-40% of agomelatine, 0-10% of nano-porous carbon dioxide, 40-90% of a pressure-sensitive adhesive, 1-30% of a transdermal penetration enhancer and 0-20% of a dispersant. The transdermal delivery preparation disclosed by the invention not only can continuously deliver the medicine in a transdermal manner for a longer time to maintain the constant blood concentration, but also is quick in transdermal absorption rate and high in transdermal absorptive amount, so that the preparation has the characteristics of stability and efficiency.
Owner:SHANGHAI MODERN PHARMA ENG INVESTIGATION CENT
Chinese medicine microemulsion preparation with enhanced percutaneous permeability and preparation method thereof
The invention provides a Chinese medicine microemulsion preparation with enhanced percutaneous permeability and preparation method thereof, which is characterized in that: the preparation contains the following raw materials in weight ratio: tripterygium alcohol extract 0.1-1.5, mixed oil phase 1-10, mixed surfactant 10-30, cosurfactant 0.1-10 and double distilled water 60-85. The preparation provided by the invention has the advantages of: good percutaneous permeability and good inclusiveness, which cause the Chinese medicine complicated components easy to be molded; thereby avoiding stimulation of oral preparation to gastrointestinal tract and first-pass effect, generating lasting and constant blood concentration, reducing administration frequency, reducing pharmaceutical toxic and side effects. Body surface administration can directly reach focus for resolving patient complaint more quickly, because the medicine can be used conveniently, and is easy to control, paint and clean; the tripterygium microemulsion preparation provided by the invention has a percutaneous permeation rate which is 6.15 times of that of tripterygium ointment with identical drug loading, and conforms to zero level release equation, and reflects high-efficient and constant-speed release characteristics.
Owner:JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Transdermal drug delivery preparation with three-dimensional mesh stereoscopic configuration and preparation method of transdermal drug delivery preparation
InactiveCN104546804AImprove complianceFast absorption ratePharmaceutical non-active ingredientsSheet deliveryBlood concentrationMedicine
The invention discloses a transdermal drug delivery preparation with three-dimensional mesh stereoscopic configuration and a preparation method of the transdermal drug delivery preparation. The transdermal drug delivery preparation with the three-dimensional mesh stereoscopic configuration is composed of a transdermal drug delivery system with the drug-loaded three-dimensional mesh stereoscopic configuration, a backing layer and an anti-sticking layer, wherein the backing layer is compounded on one side of the transdermal drug delivery system with the drug-loaded three-dimensional mesh stereoscopic configuration; and the anti-sticking layer is compounded on the other side of the transdermal drug delivery system with the drug-loaded three-dimensional mesh stereoscopic configuration. With nanoporous silica as a carrier, the defects that a preparation is low in drug loading capacity, medicines are easily separated out and crystallized to affect the transdermal absorption efficiency, the adhesion performance of a pressure-sensitive adhesive system is not ideal enough, the pressure-sensitive adhesive system is easy to age, and the medicine stability is poor are solved; the long-term lasting transdermal penetration of the medicine can be effectively achieved; the stable blood concentration can be maintained; and the preparation has the characteristics of high transdermal absorption rate, high transdermal absorption amount, stability and high efficiency.
Owner:SHANGHAI MODERN PHARMA ENG INVESTIGATION CENT
Method for extracting and separating eugenol, pharmaceutical composition containing eugenol and preparation method thereof
InactiveCN101696159AImprove gastrointestinal functionAccelerating early recovery of gastrointestinal function after abdominal surgeryOrganic active ingredientsEther separation/purificationEugenolImpurity
The invention provides a method for extracting and separating eugenol, a pharmaceutical composition containing eugenol and a preparation method thereof. The method for extracting and separating eugenol comprises the following steps: (1) removing impurity and sieving out ashes for later use; (2) putting the clove obtained in step 1 in a beater, separately adding fourfold, triple and doubled 3% sodium hydroxide solution in sequence and respectively beating for 3 minutes, and suction filtering; (3) adding acid to the sodium hydroxide solution obtained in the step 2 so as to regulate to pH5, then adding sodium chloride to the sodium hydroxide solution obtained in step 2, wherein the addition of the sodium chloride accounts for 5 percent of the sodium hydroxide solution, allowing to stand overnight at the temperature of 3-6 DEG C, and respectively taking essential oil; (4) and vacuum distilling and separating Hg of 10mm at the temperature of 124 DEG C, finally obtaining eugenol. The invention provides a method for extracting and separating eugenol which is an effective component of clove and can be used for quickening the recovery of postoperative abdomen stomach function so as to avoid or reduce postoperative intestinal obstruction, a pharmaceutical composition containing eugenol and a preparation method thereof.
Owner:王永清
Transdermal spray preparation for plastic mist membranization and preparation method of transdermal spray preparation
ActiveCN104414975APromote absorptionImprove complianceOrganic active ingredientsAntipyreticPorosityControlled release
The invention discloses a transdermal spray preparation for plastic mist membranization and a preparation method of the transdermal spray preparation. The transdermal spray preparation for plastic mist membranization comprises the following components in percentage by mass: 2%-20% of medicine, 2%-20% of mesoporous nano silica aerogel, 2%-30% of a dispersing agent, 1%-15% of atomizing agent, 1%-15% of a film-forming agent and 35-90% of a volatile solvent. The mesoporous nano silica aerogel is a controlled-release mesoporous nanometer carrier; the porosity of the mesoporous nano silica aerogel is 90%-99.8%; the aperture of the mesoporous nano silica aerogel is 20-100nm; the three-dimensional nano particle size is 2-70nm; the specific surface area is 100-1,000m<2> / g; the density is 0.003-30g / cm<3>; and the heat-conducting coefficient is 0.01-0.018w / m.k. According to the transdermal spray preparation, long-time continuous transdermal penetration of the medicine can be effectively achieved; the constant blood concentration is maintained; and the preparation has the characteristics of high transdermal absorption rate, high transdermal absorption amount and is stable and efficient.
Owner:SHANGHAI MODERN PHARMA ENG INVESTIGATION CENT
Anticoccidial compound origanum oil oral nano emulsion for poultry and preparation method thereof
InactiveCN103550406AEvenly distributedSystem transparencyOrganic active ingredientsAntiparasitic agentsBiotechnologyORIGANUM OIL
The invention relates to an anticoccidial compound origanum oil oral nano emulsion for poultry. The anticoccidial compound origanum oil oral nano emulsion is prepared from the following raw materials in percentage by weight: 1%-30% of origanum oil, 10%-40% of a surfactant, 1%-20% of a cosurfactant, 1%-20% of toosendanin, 1%-20% of a green tea extract, 1%-20% of lentinan, 0.1%-10% of procyanidine and the balance being water; the sum of the weight percentages of the raw materials is 100%. According to the oral nano emulsion, the origanum oil and the purely-natural plant extract are combined, and the oral nano emulsion with the formula is healthy and reasonable, has high safety, has double effects of health care and treatment and has an obvious anticoccidial curative effect.
Owner:HENAN SOAR VETERINARY PHARMA
Transdermal absorption formulation of total alkaloid of common monkshood root and preparation process thereof
InactiveCN1969971AAvoid reactionAvoid adverse reactionsOrganic active ingredientsAntipyreticAdditive ingredientSteroidal alkaloid
The invention discloses a frame type percutaneous absorption externally-used preparation and process for preparing it, which comprises four portions of a storage layer, an adhesive layer, a back lining layer and a protection layer, wherein the storage layer comprises the following constituents (by weight ratio): Ligusticum wallichii alkaloid extract 7.5-12 parts, frame material 50-60 parts, methyl glycol 7-15 parts, azone 0.5-3 parts, and thickening agent 0-5 parts, other ingredients 5-35 parts. The preparation can be used for treating rheumatic and rheumatoid arthritis.
Owner:HARBIN UNIV OF COMMERCE
Propranolol-eugenol type basil oil nano-emulsion medicament and preparation method thereof
InactiveCN102657697AGood blood pressure effectStable buckOrganic active ingredientsEmulsion deliveryHalf-lifeEugenol
The invention discloses a propranolol-eugenol type basil oil nano-emulsion medicament, which consists of the following raw materials in percentage by mass: 1-10 percent of propranolol, 10-30 percent of surfactant, 0-25 percent of cosurfactant, 1-15 percent of eugenol type basil oil and the balance of distilled water, wherein the mass percentage sum of the raw materials is 100 percent. A nano-emulsion has the characteristics of small emulsion drop particles, uniform distribution, low viscosity and high flowability. In a nano-emulsion dosage form, propranolol serving as a water-soluble medicament is organically combined with fat-soluble eugenol type basil oil, so that the dissolving and permeation capabilities of eugenol type basil oil are increased, and the stability and medicament effect of propranolol are enhanced. After the propranolol and the eugenol type basil oil are prepared into a nano-emulsion dosage form, the advantages of the propranolol and the eugenol type basil oil are combined, the hypertension resisting effect is enhanced remarkably, the half-life period of a medicament is prolonged, and the administration times are reduced.
Owner:NORTHWEST A & F UNIV
Tamoxifen citrate emplastrum and preparation method thereof
InactiveCN101711754AConvenient treatmentStabilize local blood drug concentrationOrganic active ingredientsSexual disorderTransdermal patchAdditive ingredient
The invention relates to a tamoxifen citrate emplastrum and a preparation method thereof. A tamoxifen citrate micro emulsion is prepared into a transdermal emplastrum, and the transdermal emplastrum is divided into four layers: an anti-adhesion layer, a viscose layer, a back lining layer and a medicine storage layer. The tamoxifen citrate micro emulsion is used as a drug effect ingredient and comprises tamoxifen citrate used as an active ingredient, polysorbate 80 used as a surfactant, propylene glycol used as a cosurfactant, pure water or distilled water, and the like. Besides the drug effect ingredient, some non-polar polymers, a plasticizer, a tackifier, transdermal enhancer and an antioxidant are also added to the emplastrum. Compared with the traditional dosage forms such as tablets, solutions, oral cavity disintegrants, dispersants and external micro emulsion preparations, the tamoxifen citrate emplastrum has the prominent advantages of safety, low toxicity, convenient and simple use and accurate drug dosage.
Owner:河南省生物工程技术研究中心
Oil-in-water type compound apramycin nano-emulsion
ActiveCN104027408ASystem transparencyImprove stabilityAntibacterial agentsOrganic active ingredientsActive agentPharmaceutical drug
An oil-in-water type compound apramycin nano-emulsion belongs to the technical field of medicines, and is composed of the compositions in percent by weight: 1%-18% of apramycin, 1%-20% of rheum officinale extractive, 15%-40% of a surfactant, 1%-25% of an auxiliary surfactant, 1%-20% of oil and 20%-80% of distilled water. The compound apramycin bacteriostatic nano-emulsion is relatively narrow in emulsion particle size, transparent in system, good in stability, relatively low in surface tension, extremely good in fluidity and convenient to administrate. Because of the compounding of rheum officinale extractive and apramycin, the bacteriostatic effect is relatively good, and because of the nano-emulsion form, apramycin is relatively easy to absorb by bodies, and the usage amount and the usage frequency of the medicine can be reduced.
Owner:HENAN SOAR VETERINARY PHARMA
Propofol flexible nano-liposome patch and application thereof
ActiveCN106214668AQuick effectGood effectNervous disorderHydroxy compound active ingredientsLiposomeColloidal Solution
The invention discloses a propofol flexible nano-liposome patch which can promote sleeping and improve the sleeping quality. The patch is composed of a propofol flexible nano-liposome solution and a substrate layer. The propofol flexible nano-liposome solution is mainly composed of propofol, phospholipids and a flexible agent, wherein the grain size of the solution is tens to hundreds nanometers, and a colloidal solution exists on the appearance. The patch has the advantages of high deformation, high hydrophilia, efficient permeability and high stability.
Owner:XIAN LIBANG PHARMA
Transdermal drug delivery preparation with drug-loaded three-dimensional mesh spatial configuration and preparation method of transdermal drug delivery preparation
InactiveCN104666279AImprove complianceFast absorption rateOrganic active ingredientsPharmaceutical non-active ingredientsDevitrificationBlood concentration
The invention discloses a transdermal drug delivery preparation with a drug-loaded three-dimensional mesh spatial configuration and a preparation method of the transdermal drug delivery preparation. The transdermal drug delivery preparation with the drug-loaded three-dimensional mesh spatial configuration is composed of a transdermal drug delivery with the drug-loaded three-dimensional mesh spatial configuration, a backing layer and an anti-sticking layer, wherein the backing layer is compounded on one side of the transdermal drug delivery with the drug-loaded three-dimensional mesh spatial configuration; the anti-sticking layer is compounded on the other side of the transdermal drug delivery with the drug-loaded three-dimensional mesh spatial configuration; and an active medicine comprises the forms of oxybutynin hydrochloride or tartrate thereof, sulfate, phosphate, fumarate and a basic group. According to the transdermal drug delivery preparation, the drug loading capacity is greatly increased; the drug loading capacity can be improved; the medicine devitrification is inhibited; the medicines are sequentially and uniformly dispersed into the transdermal drug delivery system; stable release is carried out; long-term lasting transdermal permeation of the medicines can be realized; stable blood concentration is maintained; and the preparation is high in transdermal absorption rate and high in transdermal absorption amount, and has the characteristics of being stable and efficient.
Owner:SHANGHAI MODERN PHARMA ENG INVESTIGATION CENT
Huperzine A mono-layer osmotic pump controlled release tablets
InactiveCN101485640BStable release rateConstant plasma concentrationOrganic active ingredientsNervous disorderDrug release rateCellulose acetate
Owner:普尔药物科技开发(深圳)有限公司
Aescin A liposome gel and a preparing method thereof
InactiveCN106943339APromote transdermal absorptionImprove transmittanceOrganic active ingredientsAntipyreticMentholCholesterol
Aescin A liposome gel is disclosed. The aescin A liposome gel includes aescin A, soybean phospholipid, cholesterol, carbomer, triethanolamine, EDTA.2Na, menthol, and the like. A preparing method of the aescin A liposome gel is also disclosed and includes a first step of preparing liposome and a second step of preparing the liposome gel. Compared with common gel agents, the liposome gel has better transdermal absorption effects, has a controlled release function, and can be slowly released at a certain speed, thus forming a constant plasma concentration of a medicine in skin and prolonging the treatment time of a medicine. The aescin A liposome gel also can reduce the occurrence rate of skin irritative reactions.
Owner:WUHAN AIMIN PHARMA
Oil-in-water compound antimicrobial cefazolin nanoemulsion medicine
InactiveCN104352433AImprove solubilityGuaranteed efficacyAntibacterial agentsOrganic active ingredientsCefazolinDistilled water
An oil-in-water compound antimicrobial cefazolin nanoemulsion medicine is a nanoemulsion medicament with cefazolin and an aqueous clove extract as effective components, and comprises the following components in parts by weight: 1-15 parts of cefazolin, 10-30 parts of a surfactant, 0-25 parts of a co-surfactant, 1-10 parts of aqueous clove extract, 1-20 parts of oil and 20-70 parts of distilled water. By compounding the cefazolin and the aqueous clove extract, the oil-in-water compound antimicrobial cefazolin nanoemulsion medicine is good in medicinal effect and good in antimicrobial effect; a preparation method is very simple; the oil-in-water compound antimicrobial cefazolin nanoemulsion medicine is easier to popularize.
Owner:HENAN SOAR VETERINARY PHARMA
Compound aescin A liposome hydrogel patch
ActiveCN107252431AGood transdermal absorptionHigh total transmittanceSalicyclic acid active ingredientsPharmaceutical non-active ingredientsDrugDiethylamine salicylate
The invention discloses an anti-swelling pharmaceutical composition. The composition is composed of aescin A or its salt, diethylamine salicylate according to the proportion of 0.3-1.5:2-5. The invention also discloses a compound aescin A liposome hydrogel patch containing the composition and a preparation method thereof. Compared with the prior art, the anti-swelling pharmaceutical composition has better transdermal absorption effect, anti-swelling effect and security.
Owner:WUHAN AIMIN PHARMA
Lasofoxifene tartrate emplastrum
InactiveCN103830207AConvenient treatmentStabilize local blood drug concentrationSkeletal disorderSexual disorderTransdermal patchAntioxidant
The invention discloses a lasofoxifene tartrate emplastrum preparation and a preparation method for the same. According to the preparation method disclosed by the invention, lasofoxifene tartrate micro-emulsion is prepared into a transdermal emplastrum, and the transdermal emplastrum is divided into four layers, that is, an anti-sticking layer, an adhesive layer, a backing layer and a medicine storage layer; the medicinal ingredient is lasofoxifene tartrate micro-emulsion, and is composed of lasofoxifene tartrate used as an active ingredient, polysorbate 80 used as a surfactant, propylene glycol used as a cosurfactant, pure water or distilled water and the like. Some non-polar polymers, a plasticizer, a tackifier, a transdermal accelerant and an antioxidant are further added in the emplastrum preparation disclosed by the invention besides the medicinal ingredients above. The lasofoxifene tartrate emplastrum preparation disclosed by the invention has the positive significance that compared with the existing dosage forms and tablets, the lasofoxifene tartrate emplastrum preparation has the prominent advantages of being lasting in efficacy, safe and low-toxicity, convenient, simple and sanitary to use, and accurate in medication dose.
Owner:崔书豪
Traditional Chinese medicine composition for promoting intestine peristalsis to expel flatus to prevent intestinal adhesion and preparation method thereof
ActiveCN107875370ATrigger regulationMaintain continuityOrganic active ingredientsDigestive systemIntestinal structurePeristalsis
The invention relates to a traditional Chinese medicine composition for promoting intestine peristalsis to expel flatus to prevent intestinal adhesion and a preparation method thereof. The traditionalChinese medicine composition contains the following components in parts by weight: 6-10 parts of pericarpium zanthoxyli, 10-15 parts of rhizoma zingiberis, 6-10 parts of ginseng and 20-30 parts of maltose. The preparation method comprises the following steps: mixing all components, then uniformly mixing with a matrix paste to obtain a paste; uniformly coating a non-woven fabric of a backing layerwith the paste, and then laminating, thus obtaining emplastrum. The traditional Chinese medicine composition provided by the invention is prepared by adopting pure traditional Chinese medicine, is free from injection, free from pain, good in absorption, convenient to use, extract in curative effect, rapid to take effect and economical and practical, can recover the intestinal function of a patient as soon as possible, promote intestine peristalsis and intestinal flatus expelling and prevent the occurrence of intestinal adhesion, and can overcome shortages of existing clinical treatment technology, and further can enable patients to recover the physical power as soon as possible, promote healing of the wound, reduce length of stay, relieve the family financial burden, bring convenience andgreatly facilitate the doctor and the patient.
Owner:SHENZHEN JIAN AN PHARMA CO LTD
Raloxifene emplastrum preparation and preparation method thereof
InactiveCN101700241AConvenient treatmentStabilize local blood drug concentrationOrganic active ingredientsSkeletal disorderTransdermal patchAdditive ingredient
The invention relates to a raloxifene emplastrum and a preparation method thereof. Raloxifene microemulsion is made into a transdermal emplastrum which is divided into an anti-adhesion layer, a viscose layer, a backlining layer and a medicine storage layer. The raloxifene microemulsion taken as a medical ingredient of the raloxifene emplastrum comprises the following ingredients: raloxifene taken as an active ingredient, polysorbate taken as surfactant, propanediol taken as cosurfactant, pure water or distilled water, and the like. Except for the medical ingredient, a plurality of nonpolar polymers, plasticizing agent, caking agent, transdermal enhancing agent and antioxidant are also added in the emplastrum. Compared with the prior dosage forms, such as tablets, the invention has the remarkable advantages of durable medical effect, safety, low toxicity, simple, convenient and sanitary, and accurate medical dosage.
Owner:河南省生物工程技术研究中心
Wind evil expelling sea horse plaster and its prepn
InactiveCN101020003AGood miscibilityNot easy to loseSalicyclic acid active ingredientsHydroxy compound active ingredientsMedicinal herbsIrritation
The present invention is wind evil expelling sea horse plaster and its preparation process. The medicinal material for the plaster includes methyl salicylate, nux vomica, angelica, achyranthes root, tetrandra root, ledebouriella root and other 14 kinds of Chinese medicinal materials. It is prepared through decocting partial Chinese medicinal materials, filtering, mixing, crushing, alcohol percolating, merging, mixing with matrix and other supplementary material, and other steps. It has the functions of dispelling wind and cold, promoting blood circulation and relieving pain. It is used in treating wind and cold caused numbness and aching waist and legs.
Owner:林冶
Benazepril hydrochloride-hyacinth oil nanoemulsion antihypertensive drug
InactiveCN102727721AGood blood pressure effectStable buckPowder deliverySolution deliveryAdditive ingredientHalf-life
The invention discloses a benazepril hydrochloride-hyacinth oil nanoemulsion antihypertensive drug. Raw materials for the drug comprise, by mass percentage, 1% to 18% of benazepril hydrochloride, 15% to 40% of surfactant, 0 to 20% of cosurfactant and 1% to 20% hyacinth oil, with the balance being distilled water, wherein the sum of the mass percentage of the raw materials is 100%. Nanoemulsion provided in the invention has small and uniformly-distributed emulsion droplet particles, low viscosity and good fluidity. In the dosage form of nanoemulsion, the water-soluble drug benazepril hydrochloride and fat-soluble hyacinth oil are organically combined together, which improves the solubility and permeability of hyacinth oil and the stability and efficacy of benazepril hydrochloride. When the dosage form of nanoemulsion is prepared from benazepril hydrochloride and hyacinth oil, the advantages of both benazepril hydrochloride and hyacinth oil are combined; therefore, an antihypertensive effect of the drug provided in the invention is obviously improved, the half-life of the drug is prolonged, and administration frequency is reduced.
Owner:NORTHWEST A & F UNIV
Oil-in-water type compound lomefloxacin nano-emulsion
InactiveCN104367690AImprove solubilityImprove permeabilityAntibacterial agentsOrganic active ingredientsLomenfloxacinActive agent
The invention discloses an oil-in-water type compound lomefloxacin nano-emulsion, belonging to the technical field of medicines. The nano-emulsion comprises the following components in parts by weight: 1-20 parts of herba houttuyniae aqueous extract, 5-40 parts of surfactant, 1-15 parts of co-surfactant, 1-25 parts of lomefloxacin, 1-25 parts of oil and 20-70 parts of water. The nano-emulsion disclosed by the invention is relatively narrow in latex particle size distribution, transparent in system and good in stability, has relatively low surface tension and very good fluidity, is convenient to take, and improves the solubility and penetrability of lomefloxacin to ensure that the bioavailability of a medicament is improved; and the herba houttuyniae aqueous extract is compounded with lomefloxacin, so that the antibacterial abilities of the two are mutually promoted, and the antibacterial effect is more stable.
Owner:HENAN SOAR VETERINARY PHARMA
Lipid-containing medicinal preparation, medicinal transdermal patch and preparation method of medicinal transdermal patch
PendingCN112057436ALess irritatingImprove bioavailabilityOrganic active ingredientsPowder deliveryTransdermal patchDrugs preparations
The invention relates to the field of medicines, in particular to a medicinal preparation, a medicinal transdermal patch containing the medicinal preparation and a preparation method of the medicinaltransdermal patch. The medicinal preparation comprises a coated medicine and an uncoated medicine, wherein the coated medicine comprises a medicine A and an inclusion material coating the medicine A;the inclusion material contains lipid; the uncoated medicine is a medicine B; and the medicine A and the medicine B are the same or different. The medicinal preparation and the medicinal transdermal patch provided by the invention have the advantages that an effective dose of medicine can be stably and durably (capable of reaching 7 days) released, and in addition, the controllability is high, sothat the medication requirements of patients of different degrees can be met.
Owner:江苏一全药业有限公司
Compound quercetin nanoemulsion anti-aging health care product
InactiveCN106137959ASignificant and long-lasting antioxidantVisible and long-lasting anti-aging effectOrganic active ingredientsAntinoxious agentsDiseaseAcute hyperglycaemia
The invention discloses a compound quercetin nano-emulsion anti-aging health care product. The raw materials and mass percentages thereof are: 1% to 15% of quercetin, 15% to 40% of a surfactant, and 1% to 10% of a cosurfactant 15%, oil 5%-25%, celery water extract 1%-15%, mushroom water extract 1%-15%, the rest is distilled water, and the mass percentage sum of the above-mentioned raw materials is 100%. The nano-emulsion emulsion has small particles, uniform distribution, low viscosity and good fluidity. The present invention uses the fat-soluble natural product quercetin with high anti-aging effect as the main component, supplemented with celery water extract and mushroom water extract, and has the functions of maintaining skin moisture, regulating sleep, delaying aging, and regulating immune function. It has a certain health care effect on diseases such as high blood pressure, high blood fat, high blood sugar, and heart disease.
Owner:张鸿利
Propofol flexible nano liposome patch and its application
ActiveCN106214668BInhibitory activityImprove the safety of useNervous disorderHydroxy compound active ingredientsMedicinePhospholipid
Owner:XIAN LIBANG PHARMA
Application of composition in preparation of veterinary anthelmintic drugs, veterinary anthelmintic transdermal solution and preparation method thereof
PendingCN111991411AReduce labor costsPromote percutaneous absorptionOrganic active ingredientsPharmaceutical delivery mechanismAntiparasiticAnthelmintic drug
The invention belongs to the technical field of anti-parasitic drugs, and particularly relates to application of a composition in preparation of veterinary anthelmintic drugs, a veterinary anthelmintic transdermal solution and a preparation method thereof. The transdermal solution takes isopropanol as a solvent and comprises the following components in percentage by volume: 40%-70% of glycerol methylal, 5%-15% of isopropyl myristate, a fat-soluble antioxidant, ivermectin and praziquantel, wherein the ratio of the mass of the fat-soluble antioxidant to the volume of the transdermal solution is(0.02-0.08) g: 100mL; the ratio of the mass of the ivermectin to the volume of the transdermal solution is (0.3-1) g: 100mL; and the ratio of the mass of the praziquantel to the volume of the transdermal solution is (5-15) g: 100mL. The veterinary anti-parasite composition has a wide anti-parasite spectrum, and the transdermal solution not only improves the anti-parasite spectrum, but also is small in side effect and convenient to use, and reduces the labor cost of drug delivery.
Owner:吉林吉力生物技术研究有限公司 +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com